Recent advances in understanding of multifaceted changes in the vaginal microenvironment: implications in vaginal health and therapeutics
- PMID: 35312419
- DOI: 10.1080/1040841X.2022.2049696
Recent advances in understanding of multifaceted changes in the vaginal microenvironment: implications in vaginal health and therapeutics
Abstract
The vagina endures multifaceted changes from neonatal to menopausal phases due to hormonal flux, metabolite deposition, and microbial colonization. These features have important implications in women's health. Several pre-factors show dynamic characteristics according to the phases that shift the vaginal microbiota from anaerobes to aerobes which is a hallmark of healthy vaginal environment. These factors include oestrogen levels, glycogen deposition, and vaginal microstructure. In the adult phase, Lactobacillus is highly dominant and regulates pH, adherence, aggregation, immune modulation, synthesis of bacteriocins, and biosurfactants (BSs) which are antagonistic to pathogens. Maternal factors are protective by favouring the colonization of lactobacilli in the vagina in the neonatal phase, which diminishes with age. The dominance of lactobacilli and dysbiosis in the adult phase depends on intrinsic and extrinsic factors in women, which vary between ethnicities. Recent developments in probiotics used against vaginal microbiome dysbiosis have shown great promise in restoring the normal microbiota including preventing the loss of beneficial bacteria. However, further in-depth studies are warranted to ensure long-term protection by probiotics. This review highlights various aspects of the vaginal microenvironment in different phases of growth and diverse ethnicities. Furthermore, it discusses future trends for formulating more effective population-specific probiotics and implications of paraprobiotics and postbiotics as effective therapeutics.
Keywords: Microbiome; paraprobiotics; postbiotics; probiotics; vagina.
Similar articles
-
The microbial revolution: Unveiling the benefits of vaginal probiotics and prebiotics.Microbiol Res. 2024 Sep;286:127787. doi: 10.1016/j.micres.2024.127787. Epub 2024 May 31. Microbiol Res. 2024. PMID: 38851010 Review.
-
Vaginal microbiome.Ceska Gynekol. 2018 Winter;83(5):371-379. Ceska Gynekol. 2018. PMID: 30848142 Review. English.
-
The role of lactic acid production by probiotic Lactobacillus species in vaginal health.Res Microbiol. 2017 Nov-Dec;168(9-10):782-792. doi: 10.1016/j.resmic.2017.04.001. Epub 2017 Apr 20. Res Microbiol. 2017. PMID: 28435139 Review.
-
Unravelling the vaginal microbiome, impact on health and disease.Curr Opin Obstet Gynecol. 2024 Oct 1;36(5):338-344. doi: 10.1097/GCO.0000000000000976. Epub 2024 Jul 15. Curr Opin Obstet Gynecol. 2024. PMID: 39109542 Review.
-
Vaginal Microbiota.Adv Exp Med Biol. 2016;902:83-93. doi: 10.1007/978-3-319-31248-4_6. Adv Exp Med Biol. 2016. PMID: 27161352 Review.
Cited by
-
A Healthy Vaginal Microbiota Remains Stable during Oral Probiotic Supplementation: A Randomised Controlled Trial.Microorganisms. 2023 Feb 16;11(2):499. doi: 10.3390/microorganisms11020499. Microorganisms. 2023. PMID: 36838464 Free PMC article.
-
Efficacy of transvaginal erbium laser treatment for vaginal relaxation and its impact on vaginal microenvironment indicators.Am J Transl Res. 2025 Apr 15;17(4):2701-2711. doi: 10.62347/BVZV3932. eCollection 2025. Am J Transl Res. 2025. PMID: 40385007 Free PMC article.
-
The Chinese herbal prescription Kang-Gong-Yan alleviates cervicitis by modulating metabolites and gut microbiota.Pharm Biol. 2024 Dec;62(1):341-355. doi: 10.1080/13880209.2024.2318791. Epub 2024 May 9. Pharm Biol. 2024. PMID: 39648685 Free PMC article.
-
Vaginal microbiota alterations under supraphysiological estradiol state during in vitro fertilization-embryo transfer (IVF-ET) and the association with reproductive outcomes.BMC Microbiol. 2025 Aug 12;25(1):500. doi: 10.1186/s12866-025-04242-7. BMC Microbiol. 2025. PMID: 40790561 Free PMC article.
-
Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial.PLoS One. 2025 Jan 21;20(1):e0315576. doi: 10.1371/journal.pone.0315576. eCollection 2025. PLoS One. 2025. PMID: 39836666 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources